Decision day for lecanemab

Should lecanemab receive a green light from the FDA, it would be the second new Alzheimer’s therapy to come to market in two years.

Related Keywords

California ,United States ,Idaho ,Americans ,Rachel Tetlow ,David Lim ,Lacey Lyons ,Isabella Cueto ,Angus Kingi Maine ,Ben Leonard ,Priya Singhal ,Kaustuv Basu ,Megan Messerly ,Kristi Hamrick ,Alex Ruoff ,Amy Abernethy ,Gary Harki ,Alice Miranda Ollstein ,Tony Gonzales ,Celine Castronuovo ,Daniel Payne ,Julie Steinberg ,Marty Maloney ,Katherine Ellen Foley ,Patrizia Cavazzoni ,Jon Heppen ,Amy Thibault ,Walgreens ,Bloomberg ,Mental Health Services Administration ,Regulatory Affairs ,Centers For Medicare ,Idaho Supreme Court ,Office Of Information ,American College Of Obstetricians ,Research Projects Agency For Health ,Alzheimer Association ,Carolina Supreme Court ,Northwestern University ,Medicaid Services ,Lauren Gardner ,Substance Abuse ,Advanced Research Projects Agency ,Miranda Ollstein ,American College ,Drug Evaluation ,Mitigation Strategy ,Biologic License Applications ,Senate Finance Chair Ron Wyden ,Angus King ,Cheri Bustos ,South Carolina Supreme Court ,